What's in Merck KGaA, Darmstadt, Germany's pipeline?

Merck KGaA, Darmstadt, Germany has 78 drugs in our index: 19 marketed, 0 filed, 22 in Phase 3, 11 in Phase 2, 26 in Phase 1.

Which companies overlap with Merck KGaA, Darmstadt, Germany's portfolio?

Top competitors by shared drug class: Pfizer, Instituto Valenciano de Infertilidad, IVI VALENCIA, Assistance Publique - Hôpitaux de Paris, El Shatby University Hospital for Obstetrics and Gynecology, Hospices Civils de Lyon.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/merck-kgaa-darmstadt-germany.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Merck KGaA, Darmstadt, Germany — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Merck KGaA, Darmstadt, Germany pipeline: 19 marketed, 0 filed, 22 Phase 3, 11 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

19 marketed 0 filed 22 Phase 3 11 Phase 2 26 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Efalizumab (Raptiva)	Efalizumab (Raptiva)	marketed	Monoclonal antibody (anti-CD11a)	CD11a (LFA-1 alpha subunit)	Immunology/Dermatology
Biltricide®	Biltricide®	marketed	Anthelmintic	Calcium channels in parasitic flatworms	Infectious Disease / Parasitology
Gonal -f® [r-hFSH]	Gonal -f® [r-hFSH]	marketed
Pergoveris®	Pergoveris®	marketed
Gabapentin/B-complex	Gabapentin/B-complex	marketed	Anticonvulsant/analgesic combination with vitamin supplementation	Alpha-2-delta subunit of voltage-gated calcium channels (gabapentin component)	Neurology; Pain Management
GnRH antagonist	GnRH antagonist	marketed
r-hGH	r-hGH	marketed
Colposeptine	Colposeptine	marketed			Other
GONAL f® prefilled pen	GONAL f® prefilled pen	marketed
Systemic corticosteroids/methotrexate	Systemic corticosteroids/methotrexate	marketed	Immunosuppressant combination (corticosteroid + DMARD)	Glucocorticoid receptor (corticosteroids); dihydrofolate reductase (methotrexate)	Immunology / Rheumatology
GONAL-f®	GONAL-f®	marketed
Luveris®	Luveris®	marketed	Gonadotropin; recombinant luteinizing hormone	Luteinizing hormone receptor (LHCG receptor)	Reproductive endocrinology; Fertility

Therapeutic area mix

Oncology · 8
Immunology / Neurology · 4
Cardiovascular · 3
Endocrinology · 3
Reproductive Medicine / Fertility · 2
Other · 2
Immunology, Rheumatology, Endocrinology · 1
Immunology / Rheumatology · 1
Infectious Disease · 1
Immunology/Rheumatology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Pfizer · 3 shared drug classes
Instituto Valenciano de Infertilidad, IVI VALENCIA · 2 shared drug classes
Assistance Publique - Hôpitaux de Paris · 2 shared drug classes
El Shatby University Hospital for Obstetrics and Gynecology · 2 shared drug classes
Hospices Civils de Lyon · 2 shared drug classes
Ain Shams University · 2 shared drug classes
Changchun GeneScience Pharmaceutical Co., Ltd. · 2 shared drug classes
Eli Lilly and Company · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Merck KGaA, Darmstadt, Germany:

Cite this brief

Drug Landscape (2026). Merck KGaA, Darmstadt, Germany — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/merck-kgaa-darmstadt-germany. Accessed 2026-05-17.